Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 20Carcinoma, Neuroendocrine 6von Hippel-Lindau Disease 2Pheochromocytoma 2Paraganglioma 2Pancreatic Neoplasms 2Melanoma 2Breast Neoplasms 2Vipoma 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Somatostatinoma 1Small Cell Lung Carcinoma 1Sarcoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Non functioning pancreatic endocrine tumor 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Multiple Endocrine Neoplasia Type 1 1Metastatic Digestive System Neuroendocrine Tumor G1 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

lutetium Lu 177 dotatate 1cabozantinib 1Sunitinib 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Metastatic Digestive System Neuroendocrine Tumor G1 × NET × Clear all
NCT05773274 2026-06-03

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
100 enrolled
EndocrineNET

Metastatic Digestive System Neuroendocrine Tumor G1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡